Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | Cadonilimab |
Trade Name | |
Synonyms | AK-104|AK 104|AK104 |
Drug Descriptions |
Cadonilimab is a bispecific antibody that targets CD274 (PD-L1) and CTLA-4, potentially resulting in enhanced anti-tumor immune response (PMID: 36872527). |
DrugClasses | CTLA4 Antibody 28 Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 112 |
CAS Registry Number | 2233593-44-5 |
NCIT ID | C153379 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
AK119 + Cadonilimab | AK119 Cadonilimab | 0 | 1 |
AK127 + Cadonilimab | AK127 Cadonilimab | 0 | 1 |
Anlotinib + Cadonilimab | Anlotinib Cadonilimab | 0 | 0 |
Cadonilimab | Cadonilimab | 0 | 2 |
Cadonilimab + Capecitabine + Oxaliplatin | Cadonilimab Capecitabine Oxaliplatin | 0 | 0 |
Cadonilimab + Chiauranib | Cadonilimab Chiauranib | 0 | 1 |
Cadonilimab + Lenvatinib | Cadonilimab Lenvatinib | 0 | 0 |